#Myeloid diversity in tumors: shaped by genes, location, and time. New review from Maria Nogales-Pons, Mariola Munárriz-Paños, Teresa Aceña-Gonzalo, & María Casanova-Acebes @casanova-acebes.bsky.social @cniostopcancer.bsky.social: rupress.org/jem/article/...

#CancerFocus #InnateImmunity

T cell engagers emerge as a compelling therapeutic modality. New review from Baeuerle, Grieshaber-Bouyer, Sauer, and Michaelson: rupress.org/jem/article/...

#CancerFocus #TumorImmunology #TcellEngagers

CD4⁺ T cell dysfunction in #cancer. New review from Hrishi Venkatesh and Lawrence Fong @fredhutch.bsky.social: rupress.org/jem/article/...

#CancerFocus #TumorImmunology #Immunotherapy

New review @jem.org by Venkatesh and Fong @fredhutch.bsky.social describes how tumor-reactive CD4 T cells are functionally impaired in #cancer, including similarities/differences with CD8 T cells, and how immunotherapies can help overcome this. rupress.org/jem/article/...
#CancerFocus #Immunotherapy

New review from Venkatesh and Fong @fredhutch.bsky.social describes how tumor-reactive CD4 T cells are functionally impaired in #cancer, including similarities/differences with CD8 T cells, and how immunotherapies can help overcome this. rupress.org/jem/article/...

#CancerFocus #Immunotherapy

YTHDFs as #radiotherapy checkpoints in tumor immunity. New review from Chuangyu Wen, Ralph Weichselbaum and colleagues: rupress.org/jem/article/...

#CancerFocus #TumorImmunology